Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer

Long-term cancer survivors risk development of second primary cancers (SPC). Vigilant follow-up may be required. We report outcomes of 92 patients who underwent chemoradiation for unresectable stage III non-small-cell lung cancer, with a median follow-up of 8.9 years. The incidence of SPC was 2.4 pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Takigawa, N, Kiura, K, Segawa, Y, Watanabe, Y, Kamei, H, Moritaka, T, Shibayama, T, Ueoka, H, Gemba, K, Yonei, T, Tabata, M, Shinkai, T, Hiraki, S, Takemoto, M, Kanazawa, S, Matsuo, K, Tanimoto, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360581/
https://www.ncbi.nlm.nih.gov/pubmed/17031394
http://dx.doi.org/10.1038/sj.bjc.6603422
Descripción
Sumario:Long-term cancer survivors risk development of second primary cancers (SPC). Vigilant follow-up may be required. We report outcomes of 92 patients who underwent chemoradiation for unresectable stage III non-small-cell lung cancer, with a median follow-up of 8.9 years. The incidence of SPC was 2.4 per 100 patient-years (95% confidence interval: 1.0–4.9).

Ejemplares similares